Apr 23, 2018 8:15 am EDT Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
Apr 20, 2018 8:15 am EDT Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
Apr 2, 2018 8:15 am EDT Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Mar 16, 2018 5:10 pm EDT Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
Mar 15, 2018 8:45 am EDT Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Feb 12, 2018 8:45 am EST Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
Feb 8, 2018 2:00 pm EST Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Feb 7, 2018 8:45 am EST Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
